A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo-Reference-Cited by-同舟云学术

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo

Published:2017-06-20 Issue:2 Volume:80 Page:307-315
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ueno Makoto,Li Chung Pin,Ikeda Masafumi,Ishii Hiroshi,Mizuno Nobumasa,Yamaguchi Taketo,Ioka Tatsuya,Oh Do Youn,Ichikawa Wataru,Okusaka Takuji,Matsuyama Yutaka,Arai Daichi,Chen Li Tzong,Park Young Suk,Furuse Junji

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3351-4/fulltext.html

Reference14 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, Cdl Fouchardière, Bennouna J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Chem M, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

3. Von-Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van-Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

4. Clerc P, Leung-Theung-Long S, Wang TC, Dockray GJ, Bouisson M, Delisle M-B, Vaysse N, Pradayrol L, Fourmy D, Dufresne M (2002) Expression of CCK2 receptors in the murine pancreas: proliferation, transdifferentiation of acinar cells, and neoplasia. Gastroenterology 122(2):428–437

5. Rengifo-Cam W, Singh P (2004) Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. Curr Pharm Des 10(19):2345–2358

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists;Pharmaceuticals;2023-04-30

2. Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study;Pharmaceutics;2022-03-18

3. Gamma camera imaging by radiolabeled gastrin/cholecystokinin analogs;Nuclear Medicine and Molecular Imaging;2022

4. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals;Cancers;2021-11-18

5. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain;Seminars in Oncology;2021-02